ArticleActa neuropathologica communications2016
LRRK2 contributes to monocyte dysregulation in Parkinson's disease.
Article in Acta neuropathologica communications, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- LRRK2-targeting antisense oligonucleotide in Parkinson's disease: a phase 1 randomized controlled trial.Nature medicine · 2026Trial
- Recent advances in targeting LRRK2 for Parkinson's disease treatment.Journal of translational medicine · 2025Review
- Immune mechanisms and shared immune targets in neurodegenerative diseases.Nature reviews. Neurology · 2025Review
- Infiltrating peripheral monocyte TREM-1 mediates dopaminergic neuron injury in substantia nigra of Parkinson's disease model mice.Cell death & disease · 2025Article
- TheScience translational medicine · 2024Article
- Single-cell transcriptomic and proteomic analysis of Parkinson's disease brains.Science translational medicine · 2024Article
- Transcriptomics and weighted protein network analyses of the LRRK2 protein interactome reveal distinct molecular signatures for sporadic and LRRK2 Parkinson's Disease.NPJ Parkinson's disease · 2024Article
- The interplay between monocytes, α-synuclein and LRRK2 in Parkinson's disease.Biochemical Society transactions · 2023Review
- Inflammation and immune dysfunction in Parkinson disease.Nature reviews. Immunology · 2022Review
- Immune Response Modifications in the Genetic Forms of Parkinson's Disease: What Do We Know?International journal of molecular sciences · 2022Review
- Mutant LRRK2 in lymphocytes regulates neurodegeneration via IL-6 in an inflammatory model of Parkinson's disease.NPJ Parkinson's disease · 2022Article
- α-Synuclein-containing erythrocytic extracellular vesicles: essential contributors to hyperactivation of monocytes in Parkinson's disease.Journal of neuroinflammation · 2022Article
- Pathological α-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain.Molecular neurodegeneration · 2022Article
- The Double-Faceted Role of Leucine-Rich Repeat Kinase 2 in the Immunopathogenesis of Parkinson's Disease.Frontiers in aging neuroscience · 2022Review
- Extracellular Vesicles as Novel Diagnostic and Prognostic Biomarkers for Parkinson's Disease.Aging and disease · 2021Review
- Long-Term Outcomes of Genetic Parkinson's Disease.Journal of movement disorders · 2020Article
- Advances in elucidating the function of leucine-rich repeat protein kinase-2 in normal cells and Parkinson's disease.Current opinion in cell biology · 2020Review
- Leucine-Rich Repeat Kinase 2 Controls Inflammatory Cytokines Production through NF-κB Phosphorylation and Antigen Presentation in Bone Marrow-Derived Dendritic Cells.International journal of molecular sciences · 2020Article
- The Current State-of-the Art of LRRK2-Based Biomarker Assay Development in Parkinson's Disease.Frontiers in neuroscience · 2020Review
- Multiple-Hit Hypothesis in Parkinson's Disease: LRRK2 and Inflammation.Frontiers in neuroscience · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.